Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
Existing investors CMB International – an investment arm of China Merchants Bank – Materia Medica Capital, and 3E Bioventures also participated in the funding round, according to a release. All three...
Kotak Mahindra Group hopes his longstanding experience in financial services will serve as a differentiator as it looks for deals in India's increasingly popular distressed space
Conservative sovereign wealth investors are increasingly comfortable making direct commitments to venture-oriented technology companies. The strategy appears to suit them but remains to be validated
01VC has secured institutional LP support for its second fund, which closed at $100 million. The early-stage investor plans to deploy it across industrial and enterprise deals in China and Southeast Asia